```html

Focal Segmental Glomerulosclerosis (FSGS) – A Complete Patient Guide

Overview

Focal Segmental Glomerulosclerosis (FSGS) is a disease that damages the kidney’s filtering units, called glomeruli. “Focal” means that only some of the glomeruli are affected, “segmental” indicates that only part of an individual glomerulus is scarred, and “glomerulosclerosis” refers to the scarring (sclerosis) itself.

FSGS can lead to protein loss in the urine (proteinuria) and eventually to chronic kidney disease (CKD) or end‑stage renal disease (ESRD) if untreated.

Who It Affects

• Age: Can occur at any age, but there are two peaks – childhood (especially ages 5‑10) and adulthood (30‑50 years).
• Sex: Slight male predominance (≈55 % men).
• Ethnicity: Higher incidence in African‑American, Hispanic, and Asian populations; rates are 2–3× higher in African‑American adults compared with Caucasians.

Prevalence

FSGS accounts for about 20‑30 % of primary nephrotic syndrome cases in adults and 15 % in children. In the United States, the incidence is roughly 7–8 new cases per million people per year, with an estimated prevalence of 35–50 cases per million (≈0.003–0.005 % of the population) [1] NIH, 2023.

Symptoms

Symptoms arise from loss of protein in the urine, reduced kidney function, and the body’s response to fluid shifts. Not everyone experiences every symptom.

• Proteinuria (frothy urine): Persistent foamy or bubbly urine is often the first sign.
• Edema (swelling): Typically starts in the ankles, feet, and can progress to the legs, abdomen, or face.
• Weight gain: Due to fluid retention.
• Hypoalbuminemia: Low blood albumin levels cause the fluid to leak into tissues.
• Fatigue & weakness: Result from anemia, low albumin, or reduced kidney clearance.
• High blood pressure (hypertension): Common as kidney function declines.
• Decreased urine output: May indicate advancing kidney disease.
• Hematuria (blood in urine): Less common but can occur.
• Loss of appetite & nausea: Result from toxin buildup (uremia) in later stages.
• Joint or muscle aches: Secondary to electrolyte disturbances.

Causes and Risk Factors

FSGS is classified into three major categories: primary (idiopathic), secondary, and genetic. In many cases, the exact trigger remains unknown.

Primary (Idiopathic) FSGS

• Immune system dysfunction causing damage to podocytes (specialized cells that line glomeruli).
• Often presents with rapid-onset nephrotic syndrome.

Secondary FSGS

Caused by conditions that place stress on the kidneys:

• Obesity: Excess body weight increases glomerular pressure.
• Hypertension: Chronic high pressure damages glomeruli.
• Viral infections: HIV, hepatitis B & C, and SARS‑CoV‑2 have been linked.
• Drug toxicity: Abuse of heroin, certain over‑the‑counter NSAIDs, and some chemotherapy agents (e.g., cyclosporine, tacrolimus).
• Reduced kidney mass: One kidney (solitary), congenital anomalies, or previous surgical removal.

Genetic (Hereditary) FSGS

Mutations in over 30 genes affecting podocyte structure (e.g., NPHS2, ACTN4, TRPC6) can be inherited in an autosomal‑recessive or dominant pattern. Genetic forms are more common in children and certain ethnic groups.

Risk Factors

• Family history of FSGS or other podocytopathies.
• African‑American or Hispanic ancestry.
• Obesity (BMI ≥ 30 kg/m²).
• Uncontrolled hypertension.
• Chronic viral infections (especially HIV).
• Exposure to nephrotoxic drugs or heavy metals.

Diagnosis

Diagnosing FSGS requires a combination of clinical assessment, laboratory tests, imaging, and most definitively, a kidney biopsy.

Laboratory Tests

• Urine protein quantification: 24‑hour urine collection or spot urine protein/creatinine ratio. Levels >3 g/24 h are typical of nephrotic range proteinuria.
• Serum albumin: Low (<3.5 g/dL) confirms hypoalbuminemia.
• Renal function panel: Creatinine, eGFR to gauge kidney performance.
• Lipid profile: Hyperlipidemia commonly accompanies nephrotic syndrome.
• Serologic work‑up: ANA, complements, hepatitis B/C, HIV, and anti‑PLA2R to rule out other glomerular diseases.

Imaging

• Renal ultrasound: Evaluates kidney size and excludes obstruction.
• CT or MRI: Rarely needed; may be used for complex cases.

Kidney Biopsy (Gold Standard)

Performed percutaneously under imaging guidance, the biopsy provides:

• Histologic confirmation of focal and segmental sclerosis.
• Classification of variant (e.g., collapsing, tip, perihilar) which can guide therapy.
• Assessment for secondary causes (e.g., immune complex deposits).

Complication rates are low (≈1–2 % hematoma, <0.1 % require transfusion) [2] Cleveland Clinic, 2022.

Genetic Testing

Considered when:

• Onset is before age 25.
• There is a strong family history.
• The disease is steroid‑resistant.

Treatment Options

Therapy aims to reduce proteinuria, preserve kidney function, and manage complications.

1. Medications

Immunosuppressive Therapy (Primary FSGS)

• High‑dose corticosteroids: Prednisone 0.8–1 mg/kg/day for 8–12 weeks, followed by a taper. About 50‑60 % achieve remission [3] Mayo Clinic, 2023.
• Calcineurin inhibitors: Cyclosporine or tacrolimus, especially in steroid‑resistant cases. Target trough levels: cyclosporine 100‑200 ng/mL, tacrolimus 5‑10 ng/mL.
• Mycophenolate mofetil (MMF): Often added as a steroid‑sparing agent.
• Rituximab: Anti‑CD20 monoclonal antibody; useful in refractory disease, particularly in children.
• ACTH gel: Emerging therapy with modest data.

Adjunctive Medications (All Forms)

• Renin‑Angiotensin‑Aldosterone System (RAAS) blockers: ACE inhibitors or ARBs reduce intraglomerular pressure and proteinuria (often 30‑40 % reduction).
• Statins: Treat hyperlipidemia; recommended when LDL > 100 mg/dL.
• Diuretics: Loop diuretics (furosemide) for edema; thiazides may be added.
• Antihypertensives: Target blood pressure <130/80 mmHg (or <120/80 mmHg if proteinuria >1 g/day).
• Anticoagulation: Consider low‑dose aspirin or warfarin if serum albumin <2.0 g/dL due to thrombotic risk.

2. Procedures

• Plasmapheresis: Used for rapidly progressive or recurrent FSGS after kidney transplantation.
• Kidney transplantation: Success rates are good, but recurrence occurs in ~30‑40 % of primary FSGS cases [4] WHO, 2022.

3. Lifestyle & Supportive Measures

• Dietary sodium restriction: < 2 g/day to control edema and blood pressure.
• Protein intake: Moderate (0.8 g/kg/day) unless in a catabolic state; excessive protein may increase glomerular workload.
• Weight management: Goal BMI < 30 kg/m²; weight loss can lower proteinuria.
• Smoking cessation: Reduces cardiovascular risk.
• Regular physical activity: At least 150 minutes of moderate aerobic exercise per week, tailored to kidney function.

Living with Focal Segmental Glomerulosclerosis (FSGS)

Managing FSGS is a multidisciplinary effort involving nephrologists, dietitians, pharmacists, and nurses. Below are practical tips for day‑to‑day life.

Medication Management

• Keep an up‑to‑date medication list; include dose, timing, and any side‑effects.
• Use a pill organizer or smartphone reminder app.
• Never stop steroids abruptly – taper under medical supervision.

Monitoring at Home

• Weigh yourself daily; a sudden gain of ≥2 kg may signal fluid retention.
• Check blood pressure twice a day (morning & evening).
• Inspect urine for foam; report any change to your doctor.
• Track laboratory results (protein/creatinine ratio, creatinine, albumin) and note trends.

Nutrition Tips

• Choose fresh fruits, vegetables, whole grains, and lean proteins.
• Limit processed foods high in sodium and saturated fat.
• If on a low‑protein diet, consult a renal dietitian to avoid malnutrition.
• Stay hydrated but follow your nephrologist’s fluid recommendations (often 1.5–2 L/day unless restricted).

Emotional & Social Support

• Join patient support groups (e.g., National Kidney Foundation, local FSGS forums).
• Consider counseling if anxiety or depression arises – chronic kidney disease is linked to higher mental‑health burden.
• Inform employers and educators about necessary accommodations (frequent bathroom breaks, reduced physical strain).

Follow‑Up Schedule

• Every 3–6 months: labs (creatinine, eGFR, albumin, lipid panel) and blood pressure check.
• Yearly: urine protein quantification and assessment for cardiovascular risk factors.
• More frequent visits if proteinuria rises, creatinine worsens, or medication side‑effects emerge.

Prevention

While primary FSGS cannot always be prevented, reducing modifiable risk factors can lower the chance of secondary disease and may slow progression.

• Maintain a healthy weight: Aim for BMI 18.5–24.9 kg/m².
• Control blood pressure: Keep <130/80 mmHg with lifestyle changes and medication.
• Screen for and treat viral infections: Regular HIV, hepatitis B/C testing in at‑risk populations.
• Avoid nephrotoxic substances: Limit NSAID use, avoid illicit drugs, and discuss any new medication with your doctor.
• Regular health check‑ups: Early detection of proteinuria allows prompt intervention.

Complications

If left untreated or poorly controlled, FSGS can lead to serious health problems.

• Chronic kidney disease (CKD) progression: Up to 30‑40 % of adults develop ESRD within 5–10 years [5] NIH, 2024.
• Thromboembolic events: Deep vein thrombosis or pulmonary embolism, especially when serum albumin <2 g/dL.
• Infections: Immunosuppressive therapy raises susceptibility to bacterial, viral, and fungal infections.
• Cardiovascular disease: Hypertension, dyslipidemia, and protein‑loss–related hypercoagulability increase risk of heart attack and stroke.
• Bone disease: Chronic loss of protein and vitamin D metabolism can cause osteoporosis.
• Malnutrition: Persistent protein loss may lead to muscle wasting.
• Pregnancy complications: Women with FSGS have higher rates of preeclampsia, preterm birth, and accelerated renal decline.

When to Seek Emergency Care

References

1. National Institutes of Health. “Focal Segmental Glomerulosclerosis Fact Sheet.” 2023. NIH.
2. Cleveland Clinic. “Kidney Biopsy: Procedure, Risks, and Recovery.” Updated 2022. Cleveland Clinic.
3. Mayo Clinic. “FSGS Treatment Options.” 2023. Mayo Clinic.
4. World Health Organization. “Kidney Transplantation and Recurrence of Primary Glomerular Diseases.” 2022. WHO.
5. National Kidney Foundation. “CKD Progression in FSGS.” 2024. NKF.

```